CA2977532C - Biomarqueurs pd-l2 predictifs de reponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques - Google Patents

Biomarqueurs pd-l2 predictifs de reponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques

Info

Publication number
CA2977532C
CA2977532C CA2977532A CA2977532A CA2977532C CA 2977532 C CA2977532 C CA 2977532C CA 2977532 A CA2977532 A CA 2977532A CA 2977532 A CA2977532 A CA 2977532A CA 2977532 C CA2977532 C CA 2977532C
Authority
CA
Canada
Prior art keywords
cancer
subject
sample
esophagogastric
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2977532A
Other languages
English (en)
Other versions
CA2977532A1 (fr
Inventor
Adam Bass
Sarah Derks
Gordon J. Freeman
Scott J. Rodig
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Priority claimed from PCT/US2016/020589 external-priority patent/WO2016144673A1/fr
Publication of CA2977532A1 publication Critical patent/CA2977532A1/fr
Application granted granted Critical
Publication of CA2977532C publication Critical patent/CA2977532C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention est basée sur l'identification de nouveaux biomarqueurs prédictifs de la réactivité de cancers oesophagogastriques à des inhibiteurs de la voie PD-1.
CA2977532A 2015-03-06 2016-03-03 Biomarqueurs pd-l2 predictifs de reponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques Active CA2977532C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562129094P 2015-03-06 2015-03-06
US62/129,094 2015-03-06
PCT/US2016/020589 WO2016144673A1 (fr) 2015-03-06 2016-03-03 Biomarqueurs pd-l2 prédictifs de réponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques

Publications (2)

Publication Number Publication Date
CA2977532A1 CA2977532A1 (fr) 2016-09-15
CA2977532C true CA2977532C (fr) 2024-09-10

Family

ID=

Similar Documents

Publication Publication Date Title
US10948492B2 (en) PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
US20170130271A1 (en) Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
US20170115291A1 (en) Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
US20160299146A1 (en) Kynurenine Pathway Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
WO2021150925A1 (fr) Utilisations de biomarqueurs pour améliorer une immunothérapie
US20210267991A1 (en) Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
EP3204516B1 (fr) Biomarqueurs à base d'angiopoïétine -2 utilisés pour la prédiction de la réponse de point de contrôle anti-immunitaire
WO2016061456A2 (fr) Compositions et méthodes d'identification, d'évaluation, de prévention et de traitement du cancer au moyen de modulateurs et de biomarqueurs nfs39
US20210102948A1 (en) Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
AU2019227641B2 (en) Methods for treating cancer using combinations of anti-BTNL2 and immune checkpoint blockade agents
WO2019014664A1 (fr) Modulation de biomarqueurs pour accroître l'immunité antitumorale et améliorer l'efficacité d'une immunothérapie anticancéreuse
US11852631B2 (en) Biomarkers predictive of anti-immune checkpoint response
US20220289854A1 (en) Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
US12050219B2 (en) Modulating biomarkers such as SPP to increase tumor immunity and improve the efficacy of cancer immunotherapy
CA2977532C (fr) Biomarqueurs pd-l2 predictifs de reponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques
HK40006303B (en) Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
HK40006303A (en) Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents